National Kidney Disease Education Program has initiated a serum creatinine standardization program. Glomerular filtration rate (GFR) can be re-estimated from standardized serum creatinine measurements. How the standardized estimated GFR (eGFR) influences hypertension prevalence has not been evaluated. In this study, cross-sectional data from 21 205 participants aged X18 years in the National Health and Nutrition Examination Survey 1999-2006 were analyzed. The differences between standardized and non-standardized eGFRs in the prevalence of hypertension and low eGFR were evaluated. Multiple logistic regression models were conducted to determine the association of standardized eGFR with hypertension prevalence. The prevalence of low eGFR estimated from standardized eGFR was higher than that from non-standardized eGFR (all Po0.01), except for the 2005-2006 survey. The prevalence of hypertension under standardized eGFR was not significantly different from that under non-standardized eGFR in both groups of participants with eGFR460 and eGFRp60 ml min À1 per 1.73 m 2 . Adjusted for age, education, gender, race/ethnicity, smoking, serum cholesterol and diabetes mellitus, the participants with standardized eGFRp60 ml min À1 per 1.73 m 2 had 56.1% more chance to be hypertensive patients than those with normal eGFR (Po0.0001). The difference in the relationship to hypertension prevalence between standardized and nonstandardized eGFR was not found significant.
Introduction
According to the American Heart Association, nearly 30% of adults have hypertension in the United States. Hypertension is the second most common reason for outpatient clinic visits in the United States 1-3 and a common risk factor for cardiovascular and renal diseases, such as stroke, 4 heart attack, 5 congestive heart failure, 6 arterial aneurysm 7 and chronic kidney failure. 8, 9 Although hypertension control has been the goal in public health, the prevalence of hypertension still keeps relatively high and has not been improved in the past two decades. 10, 11 Many investigators explored the relationship of risk factors to hypertension. However, most studies examined either the impact of risk factors on hypertension control among hypertensive patients, [12] [13] [14] [15] [16] [17] [18] instead of hypertension prevalence in general population, or the association of social-demographic characteristics, rather than clinical characteristics, with the prevalence of hypertension. [19] [20] [21] Several studies showed that the estimated glomerular filtration rate (eGFR) was an independent clinical predictor for hypertension, arterial stiffness and cardiovascular mortality. 16, 17, [22] [23] [24] [25] In these studies, eGFR was estimated from serum creatinine measurements, combined with subjects' age, gender and race. In most cases, serum creatinine measurements were not standardized. Non-standardized serum creatinine values can impact the estimates of eGFR and, hence, may bias the influence of eGFR on hypertension and cardiovascular outcomes. The National Kidney Disease Education Program (NKDEP) has been attempting to have all laboratories standardize serum creatinine to reference methods. 26 The National Health and Nutrition Examination Survey (NHANES) implemented a procedure to determine if serum creatinine needed to be adjusted, when compared with a method traceable to a 'gold' standard reference method (Roche coupled enzymatic assay). Standard serum creatinine measurements were provided in the NHANES database. Standardized eGFR can be derived from improved serum creatinine measurements. Equations for estimating glomerular filtration rate (GFR) from standardized (improved) creatinine have been published. 26, 27 Few studies associated the kidney function measured by eGFR with the hypertension prevalence; specifically, we have not seen any investigations regarding how standardized eGFR is associated with the prevalence of hypertension.
In this study, we calculated the standardized eGFR from improved/corrected serum creatinine measurements, using the NHANES database. The differences in the prevalence of hypertension and low eGFR between standardized and non-standardized eGFRs were evaluated. The relationship of standardized eGFR to the prevalence of hypertension was further examined by conducting multiple logistic regression models, adjusted for several demographic (example, age and gender), examination (example, body mass index (BMI)) and lab characteristics (example, diabetes, serum cholesterol) to reduce the confounding impact. We hypothesized that the prevalence of hypertension would vary with the type of eGFR (standardized and nonstandardized), and standardized eGFR would be highly associated with the prevalence of hypertension and be a good clinical index for preventing hypertension.
Materials and methods

Study sample
The study sample was extracted from the continuous NHANES program in the public NHANES data system. NHANES is a program of studies, with a stratified multistage probability sampling design to monitor the health and nutritional status of adults and children in the United States. The survey combines interviews and physical examinations. Continuous NHANES started in 1999 and has been conducted as a series of survey in five cycles between 1999 and 2008. The program has a changing focus on a variety of health and nutrition measurements to meet emerging needs. The survey examined a nationally representative sample of about 5000 persons each year. These persons were located in counties across the country, 15 of which were visited each year.
As Standard serum creatinine Serum creatinine assays on more stored specimens were used to determine if serum creatinine needed to be adjusted, when compared with a method traceable to a 'gold' standard reference method. The assigned laboratory analyzed the serum creatinine specimens using a Roche coupled enzymatic assay performed on a Roche P Module instrument (Roche Diagnostics, Mannheim, Germany). The Roche method calibrators were traceable to an isotope dilution mass spectrometric method for serum creatinine, 
Hypertension risk factors of interest
Information on age, education, gender, race/ethnicity, smoking and history of hypertension was obtained from self-reported questionnaire in each cycle of survey during 1999-2006. Age in years was reported by single year of age for persons from 1 through 84 years of age. For older adults, age in years was top coded at 85 years to reduce the risk of disclosure. Education variable reflected the highest level or grade of education for each participant and was re-coded as two levels: less than or equivalent to high school and more than high school. The race/ ethnicity variable was derived by combining responses to questions on race and Hispanic origin. Four categories were included: Hispanics, nonHispanic whites, non-Hispanic blacks and others. Smoking status was defined as smoking if participants ever smoked cigarettes, pipes or cigars or used snuff or chewing tobacco. Information on BMI and cholesterol were extracted from examination and lab tests. BMI (kg m 2 ) was calculated as body weight in kilograms divided by the square of height in meters; body weight and height were measured using the standard protocol and procedure during the examination in the Medical Examination Center (MEC). High serum cholesterol was defined as a serum cholesterol level X200 mg dl
À1
, and normal serum cholesterol as a level o200 mg dl
. Diagnosed diabetes was claimed on the basis of glycohemoglobin (HbA 1C ) test and self-report questionnaire. Participants were defined to have diabetes if HbA 1C X6.5% (http://ndep.nih. gov/) or they answered 'yes' to at least one of the interview questions: 'Have you ever been told by a doctor that you have diabetes or sugar diabetes?' or 'Are you now taking insulin?' or 'Are you now taking diabetes pills to lower blood sugar?'.
Statistical analysis
Statistical analyses were performed using SAS statistical software (SAS, version 9.2, SAS Institute, Cary, NC, USA). Descriptive statistics for subjects' characteristics, including demographics, co-morbidities and outcome measures were evaluated by normal and low eGFR groups, using w 2 -statistics for categorical variables and generalized linear model (GLM) techniques for continuous values. The study sample was a stratified multistage sample with the complex probability sampling design obtained by combining four 2-year cycles of continuous NHANES data, including characteristics from demographic, examination, lab and questionnaire. To reflect unequal probabilities of selection, non-response adjustments and poststratification adjustments, examination sampling weights were incorporated into the data analysis to obtain proper estimates and sampling errors of estimates. Using sampling weights could also adjust for the impact of oversampling African-American, Hispanic-American and individuals aged 60 years or older in the NHANES survey.
The estimated rates of low eGFR based on standardized and non-standardized eGFR were compared to examine the difference over eGFR estimation methods. The age-adjusted prevalence of hypertension was presented and tested according to standardized eGFR and non-standardized eGFR, to show how different they are in the impact on hypertension. Multiple logistic regression models were used to examine the effect of standardized eGFR on hypertension prevalence and see how the eGFR was associated with hypertension after adjustment for other risk factors. To analyze the trend of hypertension prevalence over time, we added the survey phase/cycle as an independent ordinal variable in the logistic models to account for the changes.
Results
Among participants in the study sample, 52.0 ± 0.31% were women, 12.8 ± 1.19% were Hispanic American, 71.0±1.39% were non-Hispanic whites and 11.2 ± 0.90% were non-Hispanic blacks. The average age of participants was 45.3 ± 0.29 years. In all, 8.0±0.24% of participants had low eGFR and 8.9 ± 0.28% had diabetes. Overall prevalence of hypertension between 1999 and 2006 was 29.4±0.51%. Table 1 shows the differences in participants' characteristics over two groups: eGFR460 ml min À1 per 1.73 m 2 and eGFRp60 ml min À1 per 1.73 m 2 , in which eGFR was computed from the standard serum creatinine. After adjustment for age, participants with eGFRp60 ml min À1 per 1.73 m 2 had significantly older age (Po0.01) and higher prevalence of diabetes and hypertension (both Po0.01). The differences in the proportion of participants with education of high school or below, the proportion of female subjects, the distribution of ethnicity groups, average BMI, smoking rate and the prevalence of low cholesterol were not found to be different (all P40.05) after age adjustment. Supplementary Table S1 presents the differences based on nonstandardized eGFR. Overall, the differences in characteristics by eGFR groups based on nonstandardized eGFR (Supplementary Table S1 ) did not show significant changes compared with those based on standardized eGFR (Table 1) , except for the difference in the proportion of Hispanics.
In cycle 1999-2000, we estimated 7.6 ± 0.48% of adults with low eGFR by using standardized eGFR, but the percentage went down to 2.5 ± 0.28% by using non-standardized eGFR. The prevalence of low eGFR estimated from standardized eGFR was significantly higher than the one from non-standardized eGFR (Po0.01 
Discussion
This study reported the association of standardized eGFR, which was derived from the standard serum creatinine measurements, with the prevalence of hypertension among adults in the United States. Adjusted for age, education, gender, race/ethnicity, smoking, serum cholesterol and diabetes mellitus, we found that standardized eGFR was highly associated with the prevalence of hypertension, and the participants with eGFRp60 ml min À1 per 1.73 m 2 had significantly higher chance to be hypertensive patients than those with normal eGFR. The result was consistent with previous findings generated by using the MDRD study equation for regular estimated GFR. 16, 17 Calibration of serum creatinine assays to adjust for the differences has not been standardized across laboratories, leading to substantial variation in reported values among laboratories. 29 The NKDEP has initiated a creatinine standardization program to minimize this variation. 26 Continuous NHANES survey has made efforts to implement a standard procedure to correct the creatinine measurements. We computed GFR estimates with the use of the NKDEP study equation reexpressed in 2005 26 and the original four-variable MDRD study equation developed in 1999. 28 The eGFR estimated from the NKDEP equation was standardized eGFR and that from the original equation was non-standardized eGFR. Table 2 revealed that compared with nonstandardized eGFR, the participants had significantly higher likelihood to be claimed to have low eGFR (eGFRp60 ml min À1 per 1.73 m 2 ) by using standardized eGFR. As GFR is accepted as the best overall measure of kidney function, 27 this difference in estimated GFR can influence the characterization of kidney function and chronic kidney diseases, as well as the estimated effects of eGFR on the related outcomes, such as hypertension, stroke, congested Hypertension prevalence and standardized eGFR X Liu et al heart failure and cardiovascular mortality. Choice of eGFR calculation equations in practice needs to be cautious.
In this study, the prevalence rates of hypertension were reported over two groups of participants with normal and low eGFRs dichotomized by standardized and non-standardized eGFRs, respectively (Table 3) . Overall, the prevalence rates of hypertension under standardized eGFR were equal to (tends to be slightly lower than) those under non-standardized eGFR among participants in both groups even if an eGFRo60 is more frequent in the 'standardized eGFR group'. The reason for the discrepancy lies in the participants with eGFR slightly higher or lower than the cutoff point 60 ml min À1 per 1.73 m 2 . These people are claimed to be in the group with eGFRp60 ml min À1 per 1.73 m 2 when we use standardized eGFR, whereas being in the group with eGFR 460 ml min À1 per 1.73 m 2 when we use nonstandardized eGFR ( Table 2 ). The hypertension rate among these people may come between participants with eGFR further higher than 60 ml min À1 per 1.73 m 2 and those with eGFR further lower than 60 ml min À1 per 1.73 m 2 . Hence, they can diminish prevalence rates of hypertension in both eGFR groups when we classify them on the basis of standardized eGFR. Nevertheless, in the present study, they did not significantly impact the prevalence of hypertension when using standardized eGFR compared with the non-standardized eGFR.
Further study showed that adjusted for similar risk factors in Table 4 , adults with non-standardized eGFRp60 ml min À1 per 1.73 m 2 had 59.9% more chance to have hypertension than those with normal eGFR (results not shown in Table) . However, Table 4 displayed that people with standardized eGFR less than or equal to 60 ml min À1 per 1.73 m 2 were 56.1% more likely to be hypertensives, compared with those with normal eGFR. The 3.8% difference did not attain the significant level by test. The reason may be partly explained by the finding from Table 3 that prevalence rates were slightly lower in both normal eGFR group and low eGFR group under standardized eGFR, compared with those under non-standardized eGFR. The relative hypertension risk in two eGFR groups was measured by relative odds of hypertension (low eGFR vs normal eGFR). As prevalence rates were both slightly lower in standardized eGFR or both slightly higher in non-standardized eGFR, relative odds of hypertension that can be reflected by the ratio of prevalence rates in two eGFR groups might not change significantly with eGFR calculation methods. Hence, the relative risk of hypertension (low eGFR vs normal eGFR) under standardized eGFR might not be significantly different compared with non-standardized eGFR, even after adjustment for other risk factors. Whether non-standardized eGFR could inflate the impact of eGFR on hypertension prevalence needs further study.
Continuous NHANES survey is a national program used to assess the nutrition and health of adults in the US. The large representative samples assured the analysis power to find significant results. Examination sampling weights were incorporated into the data analysis to reflect unequal probabilities of selection, non-response adjustments and post-stratification adjustments and to generalize the results to the whole population in the US. However, there were several limitations in this study. The cross-sectional NHANES survey can be analyzed to reflect only the association between eGFR and hypertension, but not the causal effect of eGFR on hypertension. There may be unrecognized measurements confounding the association between standardized eGFR and hypertension prevalence. The NKDEP and MDRD equations for estimating GFR with the use of standardized and non-standardized serum creatinine measurements were developed in populations with chronic kidney disease. 28, 30 Thus, the relationships observed in the populations with the disease may differ from those observed in healthy people, leading to increased errors when estimation equations are applied to healthy people.
As the standardized eGFR is derived from standard serum creatinine which has been recommended by the NKDEP to reduce measurement variation across laboratories, we suggest using standardized eGFR as a measure of kidney function and chronic kidney disease in the future study once standard serum creatinine measurements are available. It would be a measure more reasonable than the regular eGFR to estimate the kidney function and chronic kidney diseases and examine the impact of kidney function or other chronic kidney diseases on the prevalence of hypertension. Even though the use of standard eGFR needs to be further evaluated, this approach is more accurate than either the use of the Cockcroft-Gault equation or the measurement of creatinine clearance, even after adjustment for body-surface area and correction for systematic bias, owing to the overestimation of GFR by creatinine clearance. 26, 27 What is known about the topic?
K Hypertension has been for long a public concern worldwide. K Estimated glomerular filtration rate (eGFR) is a clinic measurement, which is associated with hypertension.
What this study adds? K Glomerular filtration rate (GFR) can be re-estimated from standardized serum creatinine measurements. K The difference between standardized and non-standardized eGFR in the association with hypertension prevalence has been evaluated by using data from the National Health and Nutrition Examination Survey 1999-2006. K The present study revealed that even though eGFRo60 ml min À1 was more frequent when classified under standardized eGFR, calculation of eGFR in a standardized manner does not improve the 'sensitivity' of eGFR in predicting arterial hypertension.
